冠状动脉介入术联合冠状动脉腔内注入替罗非班治疗急性ST段抬高性心肌梗死的临床观察

目的 探讨冠状动脉介入术联合冠状动脉腔内注入替罗非班治疗ST段抬高性急性心肌梗死(STEAMI)的有效性与安全性及对冠状动脉内血栓的影响.方法 2007年2月至2010年8月诊断明确并经冠状动脉造影证实梗死相关血管(IRA)为急性闭塞病变,且成功进行急诊冠状动脉介入治疗术(PCI)的128例STEAMI患者,随机分为试验组和对照组.试验组于冠状动脉造影后立即通过造影导管于IRA按10 μg/kg替罗非班在5 min内完成腔内注入,对照组于冠状动脉造影后立即通过造影导管于注入等容积量生理盐水.观察两组患者IRA注入替罗非班或生理盐水10 min后的冠状动脉内血栓及血管再通状况,术后院内出血并发症情况,随访两组患者术后1个月内心脏不良事件及心功能.结果 试验组IRA注入替罗非班10 min后33例血栓负荷减低,其中26例心肌梗死试验性溶栓治疗(TIMI)血流分级≥1级,对照组6例血栓负荷减低,3例TIMI≥1级,两组比较差异有统计学意义(P＜0.01).两组患者术后1个月内心脏不良事件(分别为2例和3例)比较,差异无统计学意义(P＞0.05).试验组术后1个月时的美国纽约心脏病学会(NYHA)心功能分级及左心室射血分数均优于对照组(P＜0.05).结论 冠状动脉腔内注入替罗非班联合冠状动脉介入术有助于ST段抬高性急性心肌梗死IRA的血栓消退及血管再通,有效且安全.

Abstract：

Objective To assess the clinical efficacy and safety of the combination of intracoronary tirofiban infusion(ICTI) plus percutaneous coronary intervention(PCI) in patients with acute ST-elevation myocardial infarction (STEAMI). Methods The 128 cases with STEAMI were enrolled in this study. They were randomly divided into trial group and control group. The 10 μg/kg tirofiban were infused into the infarct related artery (IRA) within 5 minutes through the cather after coronary angiography in trial group (n=64). Normal saline in matched dose was infused into IRA after coronary angiography in control group (n=64). The coronary thrombosis and revascularization status were assessed within 10 minutes after injection. Postoperative bleeding complications were observed in all cases. Adverse cardiovascular events and cardiac function were followed up within 1 month in all cases. Results There were 33 cases whose thrombus burden was reduced within 10 minutes after the infusion of tirofiban in trial group, including 26 cases of thrombolysis in myocardial infarction (TIMI) ≥1. There were 6 cases whose thrombus burden was reduced within 10 minutes after the infusion of normal saline in control group, including 3 cases TIMI ≥ 1. The coronary thrombosis and revascularization status were better in trial group rather than in control group (P＜0.01). Adverse cardiovascular events occurred in 5 cases within 1 month, including 2 cases in trial group and 3 cases in control group (P＞0.05). New York heart association functional class and ejection fraction values were better in trial group rather than in control group within 1 month (P＜0.05). Postoperative bleeding complications occurred in 14 cases by TIMI criteria , including severe and mild bleeding in 2 cases in trial group and 1 cases in control group (P＞0.05), but no significant bleeding occurred in 8 cases in trial group and in 3 cases in control group (P＜0.01). Conclusions The combination of intracoronary infusion of tirofiban plus PCI is effective and safe for thrombolysis and revascularization in IRA in patients with STEAMI.

Clinical efficacy and safety of the combination of an intracoronary tirofiban infusion plus percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction

Objective To assess the clinical efficacy and safety of the combination of intracoronary tirofiban infusion(ICTI) plus percutaneous coronary intervention(PCI) in patients with acute ST-elevation myocardial infarction (STEAMI). Methods The 128 cases with STEAMI were enrolled in this study. They were randomly divided into trial group and control group. The 10 μg/kg tirofiban were infused into the infarct related artery (IRA) within 5 minutes through the cather after coronary angiography in trial group (n=64). Normal saline in matched dose was infused into IRA after coronary angiography in control group (n=64). The coronary thrombosis and revascularization status were assessed within 10 minutes after injection. Postoperative bleeding complications were observed in all cases. Adverse cardiovascular events and cardiac function were followed up within 1 month in all cases. Results There were 33 cases whose thrombus burden was reduced within 10 minutes after the infusion of tirofiban in trial group, including 26 cases of thrombolysis in myocardial infarction (TIMI) ≥1. There were 6 cases whose thrombus burden was reduced within 10 minutes after the infusion of normal saline in control group, including 3 cases TIMI ≥ 1. The coronary thrombosis and revascularization status were better in trial group rather than in control group (P＜0.01). Adverse cardiovascular events occurred in 5 cases within 1 month, including 2 cases in trial group and 3 cases in control group (P＞0.05). New York heart association functional class and ejection fraction values were better in trial group rather than in control group within 1 month (P＜0.05). Postoperative bleeding complications occurred in 14 cases by TIMI criteria , including severe and mild bleeding in 2 cases in trial group and 1 cases in control group (P＞0.05), but no significant bleeding occurred in 8 cases in trial group and in 3 cases in control group (P＜0.01). Conclusions The combination of intracoronary infusion of tirofiban plus PCI is effective and safe for thrombolysis and revascularization in IRA in patients with STEAMI.